{"id":13097,"date":"2022-02-01T08:53:03","date_gmt":"2022-02-01T07:53:03","guid":{"rendered":"https:\/\/www.bm-t.de\/2021\/smartdyelivery-secures-additional-seven-figure-funding\/"},"modified":"2022-02-02T10:06:22","modified_gmt":"2022-02-02T09:06:22","slug":"smartdyelivery-secures-additional-seven-figure-funding","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2022-en\/smartdyelivery-secures-additional-seven-figure-funding\/","title":{"rendered":"SmartDyeLivery secures additional seven-figure funding"},"content":{"rendered":"<p><strong>Financ\u00ading round reflects con\u00adfi\u00addence in poten\u00adtial of inno\u00adv\u00ada\u00adtive nanotherapies<\/strong><\/p>\n<p>Using nanopar\u00adti\u00adcles to trans\u00adport active ingre\u00addi\u00adents to dis\u00adeased organs \u2014 with this con\u00adcept and the lat\u00adest pre\u00adclin\u00adi\u00adcal study results, Smart\u00adDye\u00adLiv\u00adery GmbH con\u00advinced its investors to invest a seven-fig\u00adure sum in this fund\u00ading round. The lead investor, bm\u2011t beteili\u00adgungs\u00adman\u00adage\u00adment th\u00fcrin\u00adgen gmbh (bm|t), as well as a pri\u00advate investor from the exist\u00ading con\u00adsor\u00adtium invested in order to enable the fur\u00adther growth of the inno\u00adv\u00ada\u00adtive com\u00adpany from&nbsp;Jena.<\/p>\n<p>\u201cWe are delighted with the devel\u00adop\u00adment results achieved and are very grate\u00adful for the con\u00adtin\u00adued trust of our investors \u2014 espe\u00adcially in the cur\u00adrent envi\u00adron\u00adment with unfore\u00adseen global chal\u00adlenges,\u201d explains CEO Dr. Marc Lehmann. \u201cThe lat\u00adest results from the non-clin\u00adi\u00adcal reg\u00adis\u00adtra\u00adtion stud\u00adies make it clear that the com\u00adpany is on the right track with the first appli\u00adca\u00adtion of the plat\u00adform tech\u00adnol\u00adogy for sep\u00adtic liver fail\u00adure,\u201d said Ste\u00adfan Jahn, Senior Invest\u00adment Man\u00adager at bm|t. The new cap\u00adi\u00adtal will be used to pre\u00adpare and exe\u00adcute the first-in-man study.<\/p>\n<h5>About SmartDyeLivery<\/h5>\n<p>Smart\u00adDye\u00adLiv\u00adery GmbH, based in Jena, Ger\u00admany, is devel\u00adop\u00ading a uni\u00adver\u00adsal plat\u00adform tech\u00adnol\u00adogy based on func\u00adtion\u00adal\u00adized nanopar\u00adti\u00adcles that can be used to trans\u00adport drugs or other car\u00adgoes to the desired organ in a tar\u00adgeted man\u00adner. The company\u00b4s aim is to pro\u00advide new ther\u00ada\u00adpeu\u00adtic options for dis\u00adeases that were pre\u00advi\u00adously untreat\u00adable or dif\u00adfi\u00adcult to treat. The inno\u00adv\u00ada\u00adtive, pro\u00adpri\u00adetary tech\u00adnol\u00adogy can also be used for diag\u00adnos\u00adtic or ther\u00ada\u00adnos\u00adtic appli\u00adca\u00adtions. For more infor\u00adma\u00adtion, please visit <a href=\"http:\/\/www.smartdyelivery.de\/en\">www.smartdyelivery.de\/en<\/a><\/p>\n<h5>About bm|t<\/h5>\n<p>bm t beteili\u00adgungs\u00adman\u00adage\u00adment th\u00fcrin\u00adgen gmbh (bm|t), head\u00adquar\u00adtered in Erfurt, is the first address for ven\u00adture cap\u00adi\u00adtal invest\u00adments in Th\u00fcrin\u00adgen, Ger\u00admany. bm|t cur\u00adrently man\u00adages nine invest\u00adment funds with a total vol\u00adume of EUR 350 mil\u00adlion and invests in inno\u00adv\u00ada\u00adtive com\u00adpa\u00adnies with strong growth poten\u00adtial across all indus\u00adtries and all phases of the com\u00adpany life cycle. More infor\u00adma\u00adtion about bm|t is avail\u00adable at <a href=\"http:\/\/www.bm-t.com\">www.bm\u2011t.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Smart\u00adDye\u00adLiv\u00adery, which uses nanopar\u00adti\u00adcles to tar\u00adget drugs to dis\u00adeased organs, secures mil\u00adlions in new funding.<\/p>\n","protected":false},"author":2,"featured_media":13094,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[216],"tags":[176,177,210,159,171],"class_list":["post-13097","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-2022-en","tag-bm-t-en","tag-bmt-en","tag-investeepartner","tag-investment-en","tag-thuringia"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/13097","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=13097"}],"version-history":[{"count":0,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/13097\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media\/13094"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=13097"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=13097"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=13097"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}